Thelansis

 Von Hippel-Lindau (VHL) disease is a rare autosomal dominant tumor syndrome affecting multiple organ systems. It results from a mutation in both alleles of the VHL gene on the short arm of chromosome 3. VHL patients inherit one mutant VHL allele from a parent and develop the disease when the second normal copy is lost or disabled. This genetic disorder is characterized by fluid-filled cysts and benign tumors in various organs, often with a potential for malignancy. Common VHL-associated tumors include central nervous system hemangioblastomas, neuroendocrine tumors, pheochromocytomas, retinal angiomas, middle ear tumors, and renal cell carcinomas (RCC). ·        The global prevalence ranges from 1.5 to 2.5 cases per 36,000 to 91,000 people, and central nervous system involvement is observed in 21% to 72% of VHL patients. Thelansis’s “Von Hippel-Lindau (VHL) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 20...

 Von Hippel-Lindau (VHL) disease is a rare tumor syndrome of autosomal dominant inheritance involving multiple organ systems. The genetic alteration responsible for this syndrome is a mutation in both of the alleles of the VHL gene located on the third chromosome's short arm. VHL syndrome patients inherit a single parental mutant VHL allele alone and develop the disease when a second wild copy is disabled or lost. VHL syndrome is a rare genetic disorder distinguished by the fluid-filled visceral cyst and benign tumor in various organ systems with a propensity for malignant transformation. Central nervous system (CNS) hemangioblastomas, neuroendocrine tumors, pheochromocytomas, retinal angiomas, middle ear tumors, and renal cell carcinomas (RCC) are some of the most prevalent VHL-linked tumours. ·        The worldwide prevalence is between 1.5 to 2.5 cases in 36,000 to 91,000 population. Central nervous system involvement is reported in 21% to 72% of ...